Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BioDay Registry: Prospective, Observational Data Collection Regarding the Use of New Systemic Treatment Options in Patients With Atopic Diseases in Daily Practice

Next Previous
Trial Profile

BioDay Registry: Prospective, Observational Data Collection Regarding the Use of New Systemic Treatment Options in Patients With Atopic Diseases in Daily Practice

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BioDay; Dutch BioDay Registry
  • Sponsors Regeneron Pharmaceuticals; Sanofi

    • Most Recent Events

    • 13 May 2023 Primary endpoint (The mean EASI and Numeric Rating Scale (NRS)-pruritus after start of tapering) has been met, as per results published in the British Journal of Dermatology.
    • 13 May 2023 Results (n=595) assessing the patient-centered dupilumab dosing regimen in daily practice, to assess prognostic factors for successful tapering and to estimate medication-related cost savings of dupilumab in atopic dermatitis patients, published in the British Journal of Dermatology.
    • 09 Jan 2023 Results (n=38) of sub-analysis and safety analysis assessing effectiveness and safety of upadacitinib on AD and on HE in patients with AD published in the Contact Dermatitis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top